Wockhardt Mira Road Achieves Breakthrough in High-Risk ABO-Incompatible Kidney Transplant

Wockhardt Mira Road Achieves Breakthrough in High-Risk ABO-Incompatible Kidney Transplant | Quick Digest
Wockhardt Hospitals, Mira Road, successfully performed a highly complex and high-risk ABO-incompatible kidney transplant on a 28-year-old patient with End-Stage Renal Disease and Chronic Immune Thrombocytopenic Purpura, marking a significant advancement in renal care in India. This procedure highlights the hospital's expertise in overcoming challenging medical barriers to provide life-saving treatment.

Key Highlights

  • Wockhardt Mira Road performed a highly complex ABO-incompatible kidney transplant.
  • Patient had ESRD and critical low platelets due to ITP, making it high-risk.
  • Mother selflessly donated her kidney despite blood group incompatibility.
  • Intensive desensitization protocol and meticulous surgery ensured success.
  • This expands living donor pool for patients facing blood group mismatch.
  • The achievement signifies advancement in advanced renal care in India.
Wockhardt Hospitals, Mira Road, has achieved a significant milestone in advanced renal care by successfully performing a highly complex and exceptionally high-risk ABO-incompatible kidney transplant. This landmark procedure involved a 28-year-old patient who was grappling with life-threatening medical challenges, specifically End-Stage Renal Disease (ESRD) combined with Chronic Immune Thrombocytopenic Purpura (ITP). The patient's condition was further complicated by a critically low platelet count of 25,000 following a prior splenectomy, which substantially increased the risk of severe bleeding during the surgical process, classifying the transplant as exceptionally high-risk. In a profound act of courage and love, the patient's mother stepped forward to donate her kidney, despite a blood group incompatibility. This selfless decision formed the cornerstone of the life-saving journey, underscoring the extraordinary bond between mother and child. To navigate the complexities and ensure a successful outcome, the medical team at Wockhardt Hospitals, Mira Road, implemented an intensive desensitization protocol. This involved multiple sessions of plasmapheresis and advanced immunotherapy, designed to effectively reduce antibody levels and stabilize the patient's platelet count before the surgery commenced. The transplant surgery demanded meticulous precision, vigilant intraoperative management, and comprehensive postoperative care to safeguard the transplanted organ and prevent potential complications. Dr. Puneet Bhuwania, Consultant Nephrologist, who spearheaded the transplant planning and immunological management, emphasized the challenging nature of the case due to its multifaceted medical complexities. He credited the successful outcome to careful planning, stringent monitoring, and the seamless teamwork of the entire medical staff, alongside the inspiring courage of the mother and patient. The surgical team included Dr. Jayesh Dhabalia, Consultant Urologist, Andrologist & Transplant Surgeon, and Dr. Pradeep Prabhakar Vyavahare, Consultant Urologist, Uro-Oncologist, Andrologist & Kidney Transplant Surgeon. The success of this highly complex ABO-incompatible transplant is particularly relevant in India, a country where kidney transplantation programs heavily rely on living donors, and the availability of deceased donors is comparatively low. ABO incompatibility has historically posed a significant barrier to transplantation, as it means the donor and recipient have different blood types, leading to a high risk of the recipient's immune system rejecting the transplanted organ. However, advancements in desensitization protocols have made ABO-incompatible transplants a safe and effective alternative for patients who lack a blood-group-compatible living organ donor, thereby expanding the available donor pool. These protocols typically involve administering drugs like Rituximab to reduce B-cells, which produce antibodies, and employing techniques such as plasma exchange or immunoadsorption to remove existing antibodies from the patient's blood. Studies from India indicate that ABO-incompatible kidney transplantation, while posing challenges like a higher incidence of short-term complications such as infections and rejection, can achieve patient and graft survival rates comparable to ABO-compatible transplants in the long term. For instance, a study reported patient survival rates often exceeding 90% at one year. These procedures are crucial in addressing the growing need for kidney transplants in India, where a significant portion of potential living donors are incompatible due to ABO mismatch. Wockhardt Hospitals, Mira Road, has consistently demonstrated its commitment to advanced renal care. This recent high-risk transplant follows other significant achievements, including the completion of 50 successful kidney transplants and the performance of their first Swap Kidney Transplant involving two ABO-incompatible donor-recipient pairs in March 2025. A 'swap kidney transplant' or 'paired kidney exchange' allows incompatible donor-recipient pairs to exchange kidneys with other incompatible pairs, enabling both recipients to receive a compatible organ. These simultaneous surgeries across multiple operating rooms require exceptional coordination and expertise, further solidifying Wockhardt Mira Road's position as a leader in nephrology and kidney transplantation. The hospital's continued efforts contribute significantly to improving the quality of life for individuals suffering from kidney-related ailments across India.

Frequently Asked Questions

What is an ABO-incompatible kidney transplant?

An ABO-incompatible kidney transplant is a procedure where the kidney donor and recipient have different blood types (e.g., a Group A donor to a Group B recipient). This was traditionally a barrier to transplantation due to the risk of the recipient's immune system rejecting the organ. However, with modern desensitization protocols, these transplants are now possible and successful, especially crucial when a compatible donor is unavailable.

Why are ABO-incompatible transplants significant for India?

ABO-incompatible transplants are highly significant in India because the country relies heavily on living organ donors due to a low deceased donor rate. A substantial portion of willing living donors are incompatible with their recipients due to blood group mismatches. ABOi transplants expand the potential donor pool, offering a life-saving option to many patients who would otherwise be unable to receive a transplant.

What makes an ABO-incompatible transplant 'high-risk'?

An ABO-incompatible transplant can be considered 'high-risk' due to several factors. The primary challenge is the recipient's immune system attacking the incompatible blood type antigens on the donor kidney. This necessitates intensive desensitization treatments before and after surgery. Additional patient comorbidities, such as a critically low platelet count from conditions like Chronic Immune Thrombocytopenic Purpura (ITP) as seen in the Wockhardt case, further elevate the risk of complications like severe bleeding during surgery.

What is the success rate of ABO-incompatible kidney transplants in India?

Studies from India have shown encouraging success rates for ABO-incompatible kidney transplants. Patient survival rates typically exceed 90% at one year, with graft survival rates (the transplanted kidney continuing to function) also being high, often between 87-95% at one year. While there's a slightly increased risk of complications like infection and rejection compared to compatible transplants, outcomes are approaching those of ABO-compatible procedures.

What desensitization protocols are used for ABO-incompatible kidney transplants?

Desensitization protocols for ABO-incompatible kidney transplants aim to reduce or remove antibodies against the donor's blood type. Common components include administering Rituximab, a medication that targets antibody-producing B-cells, several weeks before the transplant. Additionally, antibody removal techniques like plasma exchange (plasmapheresis) or immunoadsorption are used to filter out circulating antibodies from the patient's blood. Immunosuppressant medications are also started before the surgery to prevent rejection.

Read Full Story on Quick Digest